Quintiles leads several initiatives related to real-world research and registries, including developing user guides for AHRQ on using registries to evaluate patient outcomes and developing quality principles for observational research. Quintiles also leads efforts to create a central index of patient registries and assists in monitoring medical products in Europe. Quintiles participates in developing innovative methods in pharmacoepidemiology and helps collect and transmit adverse event data electronically.
This presentation provides an overview of each Meaningful Use Menu Set Measure as well as its required threshold so that you can learn how to put the Meaningful Use Menu Set Measures into practice.
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Covance
Getting a medical device to the patient takes more than good technology in today's environment. Compelling evidence and convincing value proposition matter. Competing priorities and differing stakeholder definitions of value are driving the need for creative, connected strategies to get the most from each step in the development process. And - as evidence is gathered - it should be used to inform and iterate regulatory, reimbursement and clinical post-market strategies.
: Intralign’s Rep-less Program empowers providers to successfully navigate healthcare reform through better control of the episode of care – which includes reducing the influence of the sales rep.
This presentation provides an overview of each Meaningful Use Menu Set Measure as well as its required threshold so that you can learn how to put the Meaningful Use Menu Set Measures into practice.
Medical Device and Diagnostics Solutions for Every Stage of Your Product's De...Covance
Getting a medical device to the patient takes more than good technology in today's environment. Compelling evidence and convincing value proposition matter. Competing priorities and differing stakeholder definitions of value are driving the need for creative, connected strategies to get the most from each step in the development process. And - as evidence is gathered - it should be used to inform and iterate regulatory, reimbursement and clinical post-market strategies.
: Intralign’s Rep-less Program empowers providers to successfully navigate healthcare reform through better control of the episode of care – which includes reducing the influence of the sales rep.
7th Pharmacovigilance 2014 “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management" 21st November 2014, Kohinoor Continental Hotel, Mumbai, India Greetings from Virtue Insight, I am happy to invite you and your colleagues to be a sponsor / delegate for our upcoming conference. The “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management” at 7th Pharmacovigilance 2014 on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.Contact:-Tel: +91 9677590192 Email: dinesh@virtueinsight.co.in
I am writing to make you aware of our upcoming event:- 7th Pharmacovigilance 2014 taking place on 21st November 2014, Kohinoor Continental Hotel, Mumbai, India.
The Latest Regulations, Simplified: MU, PQRS & MIPSathenahealth
Changing governmental regulations for the advancement of healthcare is more than difficult and we have simplified these changes to keep you up to date.
These slides use concepts from my (Jeff Funk) course on Business Models at National University of Singapore to analyze the business model for Theranos. Theranos provides diagnostic testing for consumers that is faster and cheaper than the existing system. Its tests are done in easy to access pharmacies (e.g., Walgreens) as opposed to hard-to reach doctors’ offices. The tests use small bio-electronic integrated circuits (ICs) instead of large scientific instruments. These ICs utilize micro-fluidic channels that require a pin-prick of blood instead of a vial of blood, which makes the tests more appealing and faster than the traditional tests. The slides describe the value proposition, method of value capture, customers, scope of activities, and method of strategic control for Theranos.
Is mHealth Prescribing: Dead or Thriving?AppScript
App rating is happening everywhere in the ecosystem, but without putting apps in practice, evaluating the prescribing data and patient feedback, we only have half the story. Learn about the prescribing data, rating and scoring methodologies and the evidence of the growing promise of mobile health curation, discovery and distribution.
Global Discovery & Developement Innovation Forum 29016
Observational research and registries
1. Real-World & Late Phase Research
The right approach
for the right question
Observational research
& registries
Initiatives
AHRQ Registries User’s Guide –
www.effectivehealthcare.ahrq.gov
Quintiles leads the development of the
Agency for Healthcare Research and
Quality (AHRQ) user’s guide, Registries
for Evaluating Patient Outcomes.
AHRQ OCER User’s Guide –
www.effectivehealthcare.ahrq.gov
Quintiles leads the development of
AHRQ user’s guide, Developing a
Protocol for Observational Comparative
Effectiveness Research.
GRACE Principles –
www.graceprinciples.org (Good
ReseArch for Comparative Effectiveness)
Quintiles develops quality evaluation
principles for observational research.
ROPR (Registry of Patient Registries)
Quintiles leads the effort to create a
central index of patient registries.
ENCePP®
– www.encepp.eu
(European Network of Centres for
Pharmacoepidemiology and
Pharmacovigilance)
Quintiles assists the monitoring of
post-market medical products in Europe.
PROTECT-EU – www.imi-protect.eu
(Pharmacoepidemiological Research on
Outcomes of Therapeutics by a
European ConsorTium)
Quintiles helps develop innovative
methods in pharmacoepidemiology and
pharmacovigilance.
ASTER-D (Adverse Event Spontaneous
Triggered Electronic Reports for Devices)
Quintiles participates in a pilot approach
to collecting and transmitting adverse
event data electronically.
Connecting
insights
950 Medical Doctors
900 PhDs
13 Therapeutic Centers
of Excellence
Superior
delivery
Quintiles named as
Phase IV industry leader
in ISR 2014 report amongst
CRO Quality Benchmarking
Phase IV Service Providers
Better
outcomes
Quintiles helped develop or
commercialize 100% of the
Top 100 best-selling products
or compounds of 2013
Quintiles is a Fortune 500
company
Embrace
value-based
healthcare
Turn clinical evidence and
patient insight into a clear and
convincing value story
Maximize
commercial
value
Achieve and sustain peak
commercialization faster
through better market access
and channel strategies
Achieve
better patient
outcomes
Improve patient care using
real-world measures and
engagement
Access global
scale with local
knowledge
Leverage the industry’s
largest integrated service
infrastructure to gain local
insight and market access